ArticleArtificial intelligence review2026
Artificial neural networks fighting real neural decline: a systematic review of AI in Alzheimer's research.
Article in Artificial intelligence review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pain in Alzheimer's Disease: Disrupted Multilevel Integration of Nociception, Affective Processing and Clinical Expression Across Clinical and Preclinical Evidence.Life (Basel, Switzerland) · 2026Review
- The application of AI-driven digital phenotyping and interventions in neuropsychiatric disorders.Frontiers in psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a major global health challenge, with Artificial Intelligence (AI) increasingly recognized as a transformative tool for early detection, disease progression modeling, and therapeutic discovery. This systematic review, conducted in accordance with PRISMA guidelines, analyzed 156 peer-reviewed studies published between 2010 and 2024, identified from four major databases (Scopus, PubMed, Web of Science, IEEE Xplore). A particular emphasis was placed on multimodal approaches that integrate neuroimaging, genetics, biomarkers, and clinical data to improve accuracy and translational value. To organize this fragmented field, we introduce a novel Layered Framework that categorizes AI applications into four domains: Early Detection, Disease Progression Modeling, Therapeutic Discovery, and Real-World Integration. In addition, we applied ARIMA-based forecasting to project research trajectories through 2030, which revealed generative models and transformer architectures as the fastest-growing and most promising methodologies. The review highlights substantial advances in early detection and multimodal fusion, particularly through deep learning, while also identifying persistent challenges such as limited model generalizability, ethical concerns, and underexplored clinical implementation. Addressing these barriers will require multi-cohort validation, interpretable AI, and equity-driven model development. By consolidating evidence and forecasting future directions, this review provides a roadmap for accelerating precision-driven innovations in Alzheimer's care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.